Tier 2 — strong

The effect of supplementation with type I and type III collagen peptide and type II hydrolyzed collagen on pain, quality of life and physical function in patients with meniscopathy: a randomized, double-blind, placebo-controlled study

Ahmet Serhat Genç, Ali Kerim Yılmaz, Berna Anıl, Esra Korkmaz Salkılıç, Enes Akdemir, Berna Güzel, Ahmet Mor, Hacı Ahmet Yarar, Nizamettin Güzel, Lokman Kehribar
BMC Musculoskeletal Disorders 2025 26:17

Bibliography

PubMed
PMID 39755603
PubMed Central
PMC11699701
DOI
10.1186/s12891-024-08244-w
Trial registry
View on ClinicalTrials.gov Registered trial — results not yet published in a peer-reviewed journal.
Funding
The paper states that the research received no external funding.
Competing interests
The authors declared no competing interests.

Study snapshot

DesignRandomized, double-blind, placebo-controlled clinical trial
ModelAdults with grade 1–2 meniscopathy
Sample32 (17 active, 15 placebo)
InterventionNaturagen® 4 Joint for eight weeks: Type I/III collagen peptides and Type II hydrolyzed collagen plus glucosamine sulfate, chondroitin sulfate, MSM, hyaluronic acid, vitamin C and olibanum; matched placebo.
Duration8 weeks
EndpointsVAS pain; WOMAC; KOOS-PS; Oxford Knee Score; Tampa Scale for Kinesiophobia; SF-12; LEFS; Foot Function Index; Proprioception; Timed Up and Go; 6-minute walk; 5-times sit-to-stand; Stair-climbing test; Berg Balance Scale; Leg and back strength

What the study showed, in plain terms

This small eight-week trial found improvements in some symptom and quality-of-life measures in people with meniscopathy using a multi-ingredient Naturagen 4 Joint product. Because the sachet contained several active joint ingredients, it cannot establish that collagen alone caused the benefits.

Key findings

Pain, kinesiophobia, quality-of-life and some foot-function measures improved; several functional tests did not differ significantly. The reported leg-strength p value was 0.057, which does not meet a conventional two-sided 0.05 significance threshold despite being described as near-significant.

What this study can and cannot tell us

Only 32 participants; multi-ingredient intervention; short duration; retrospective trial registration; many outcomes increase multiplicity concerns; not a study of DoNotAge's finished product.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology